7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,884.90

-146.50

-3.63%

77,384.83

+326.39

+0.42%

Crude Oil Dec 26

102.95

+0.95

+0.93%

US Private Equity

10,932.82

-7.68

-0.07%

NasdaqGS - Nasdaq Real Time Price USD

Monte Rosa Therapeutics, Inc. (GLUE)

10.76 -0.11 (-1.01%)

At close: October 30 at 4:00:01 PM EDT

10.76 0.00 (0.00%)

After hours: October 30 at 4:00:16 PM EDT

Trade GLUE on Coinbase

Loading Chart for GLUE

Chart Range Bar

Interval:

In partnership with ChartIQ

Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)

Are Options Traders Betting on a Big Move in Monte Rosa Therapeutics Stock?

Are Options Traders Betting on a Big Move in Monte Rosa Therapeutics Stock?

Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study

Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk

Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk

Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone

Novartis (NVS) Just Handed Monte Rosa (GLUE) A $50M Milestone

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

Mobilize your Website

View Site in Mobile | Classic

Share by: